ARA-290 is an 11-amino acid helix B surface peptide (HBSP) derived from erythropoietin (EPO), designed to activate the innate repair receptor (IRR) β the heterodimer of EPO receptor (EPOR) and Ξ²c β without activating the classical EPOR homodimer responsible for erythropoiesis. This separation allows tissue repair and anti-inflammatory research without hematopoietic side effects.
CAS 1208243-50-8 | MW 1279 DaActivates EPOR/Ξ²cR heterodimer (IRR) on tissue repair cells without triggering EPOR homodimer-mediated erythropoiesis.
Clinical data shows ARA-290 reduces small fiber neuropathy pain β a validated endpoint in published human trials.
Activates JAK2/STAT5 and PI3K/Akt survival pathways in neurons and pancreatic Ξ²-cells, reducing stress-induced apoptosis.
Protects pancreatic islet cells from cytokine and oxidative stress β studied in diabetes and metabolic disease models.
Dahan et al. (2013) conducted a Phase 2 trial showing ARA-290 28-day treatment significantly reduced pain and improved sensory nerve function in patients with sarcoidosis-associated small fiber neuropathy.
Mol Med. 2013;19:1β7Patel et al. showed ARA-290 protected neurons from ischemia-reperfusion injury via IRR-mediated anti-apoptotic signalling without affecting red cell production.
Proc Natl Acad Sci. 2011;108(35):14658β14663Piccoli et al. demonstrated 4-week ARA-290 treatment improved HbA1c and neuropathic symptoms in type 2 diabetics with peripheral neuropathy.
Diabetes Care. 2015;38(8):1552β1561Phase II trials: 4mg SC daily for 28 days. Research protocols use 4β20 nmol/kg IV or SC in rodent models. Endpoints: nerve conduction studies, intraepidermal nerve fiber density (skin biopsy), pain scales, apoptotic markers (caspase-3), and inflammatory cytokines.
| Full Name | ARA-290 (HBSP β Helix B Surface Peptide) |
| CAS Number | 1208243-50-8 |
| Molecular Weight | ~1279 Da |
| Origin | EPO helix B surface peptide derivative |
| Target | Innate Repair Receptor (EPOR/Ξ²cR) |
| Purity | β₯99% by HPLC |
| Storage | β20Β°C, desiccated |
